B+
Bull case
25%
Probability
Target price
$130.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
BNTX
BioNTech SECNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is a cash-backed oncology transition: BioNTech's verified Q1 filing cited €16.8 billion of cash, cash equivalents, and securities, six late-stage 2026 data readouts, and five additional pivotal pumitamig trials with Bristol Myers Squibb. Positive data and partner validation could support multiple expansion.
Posture
Mixed
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bullish as of 2026-09-11.
What can break
Declining or seasonal COVID vaccine demand may keep revenue visibility weak.
Momentum
60
Value
50
Sentiment
65
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $95.00 · Bull $130.00 · Bear $70.00Analysis 2026-08-05; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $118.87
Why
Momentum60 · Δ7d -0.0
Value50 · Δ7d -0.0
Sentiment65 · Δ7d +5.8
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-09-11.
- • Sentiment remains the lead driver in the composite, 7D delta +5.8.
Contradictions & invalidation
- • Declining or seasonal COVID vaccine demand may keep revenue visibility weak.
- • Founder and leadership transition plans could add execution uncertainty during the oncology shift. [#SEC-6K-2026-05-05]
- • COVID revenue remains seasonal and pressured while R&D investment and losses persist.
Catalyst clock
2026-08-05
Post-print skepticism and COVID revenue erosion
Lead driver: Sentiment · See AI snapshot
Momentum
60
9% active weight
Current posture
7d trendImproving
Δ7d
-0.0
Δ21d
+4.4
Value
50
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-2.0
Sentiment
65
62% active weight
Current posture
7d trendImproving
Δ7d
+5.8
Δ21d
+16.5
Why this grade
Composite grade C. Momentum 60.3 / Value 49.8 / Sentiment 64.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-05. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$95.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$70.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$23.01B
Beta
1.49
Shares Out
251.2M
P/E (TTM) · Derived
-17.3
P/S (TTM)
6.30
P/FCF (TTM) · Derived
43.71
Rev YoY
-58.5%
EPS YoY
+108.4%
Gross Margin
+63.9%
Op Margin
-37.6%
Net Debt
-$17.12B
Current Ratio
7.85
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data